期刊文献+

58例注射用药品不良反应监测与报告分析 被引量:4

58例注射用药品不良反应监测与报告分析
暂未订购
导出
摘要 目的分析引起药品不良反应(ADR)的相关因素,指导临床合理用药和规范操作。方法回顾性分析发生不良反应的药品种类、临床表现并进行调查和统计。结果 58例药品不良反应报告中,抗菌药物引起药品不良反应35例,占总例数的60.34%,其次为中药制剂15例,占总例数的25.86%;其他为8例,占总例数的13.80%。结论临床加强药品不良反应的监测工作,将存在的问题及时反馈,并运用计算机系统建立药品不良反应数据库,为临床提供准确及合理用药的数据服务,有效减少药品不良反应的发生。 Objective To analyze related factors of our cause adverse drug reaction, guide clinical rational drug use and standardized operation. Methods Retrospective research method, to involving adverse drug reaction drug types, clinical manifestation, and the adverse drug reaction were investigated, classification statistical analysis. Results 58 cases of adverse drug reaction report, antibacterial drugs cause adverse drug reaction 35 cases, accounting for 60.34% of the total cases of time, followed by traditional Chinese medicine preparation 15 cases, accounting for 25.86% of the total cases of time; For the other 8 cases, accounting for 13.80% of the total cases of time. Conclusion Through the analysis of inductive, guidance on how to strengthen our adverse drug reaction monitoring work, will existing problems timely feedback to clinical, and use the computer system to establish the database of adverse drug reaction, to provide accurate and for clinical rational drug use of data service, effectively reduce the occurrence of adverse drug reaction.
出处 《当代医学》 2013年第6期130-131,共2页 Contemporary Medicine
关键词 注射用药品 不良反应 监测 分析 Injectable drugs Adverse reaction Monitoring Analysis
  • 相关文献

参考文献7

二级参考文献20

  • 1叶爱琴,王建平.中药注射剂的不良反应与上市后再评价[J].医药导报,2006,25(12):1338-1340. 被引量:42
  • 280 Postmarketing reporting of adverse experiences[ R].The Code of Federal Regulations, FDA, USA, 21CFR600.80Sec.600
  • 3Current Problems in Pharmacovigilance Committee on Safety of Medicines [R], Medicines Control Agency, UK
  • 4Medicine Problem Report [ R], Therapeutic Goods Administration, Australia
  • 580 Postmarketing reporting of adverse drug experiences[R].The Code of Federal Regulations, FDA, USA,21CFR314.80 Sec.314
  • 6305 Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved new drug applications[R].The Code of Federal Regulations, FDA, USA,21CFR310.305 Sec.310
  • 7Guidance for Industry, Pharmacovigilance of Veterinary Medicinal Products: Management of Periodic Summary Update Reports (PSUs) [R] , VICH GL29, USA
  • 8Guidance for Industry, Postmarketing Safety Reporting for Human Drug and Biological, Products Including Vaccines[R].FDA, USA
  • 9Principles of Providing the World Health Organization with Pharmacovigilance Information, Human Medicine Evaluation Unit [R], the European Agency for the Evaluation of Medicinal Products
  • 10Conduct Pharmacoviggilance for Centrally Authorised Products, Human Medicine Evaluation Unit [R], the European Agency for the Evaluation of Medicinal Products

共引文献81

同被引文献31

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部